

Subject: Specialised Services Circular (SSC)
Sent on behalf of: Chair of the SW Specialised Service Circular Group

Dear Colleagues,

Please find attached the following Specialised Services Circular(s):

SSC Number	SSC Title	Trusts approved to prescribe in accordance with the SSC, providing appropriate internal governance arrangements are in place
2703	Clinical Commissioning Policy 201101: Teriparatide for Osteoporosis in Men (Adults) NHS England	University Hospitals Bristol and Weston Royal United Hospitals Bath North Bristol Trust University Hospitals Dorset Torbay and South Devon NHS Foundation Trust Royal Cornwall Hospital Trust Somerset NHS Foundation Trust Royal Devon University Hospital University Hospital Plymouth Great Western Hospitals

Is an implementation plan required from all SW trusts (regardless of commissioned status) for this SSC? No

For all other South West region trusts this is for information only.

Trusts should ensure that use is registered on the Blueteq system (if appropriate).

Treatment will only be funded where the drugs minimum dataset is fully and accurately populated.

Please direct any queries to: england.speccomm-southwest@nhs.net

All Chief Executives
All Medical Directors
All Chief Pharmacists

Specialised Commissioning South West
NHS England
100 Temple Street
Bristol
BS1 6AG

Email: england.speccomm-southwest@nhs.net

30th August 2024

Dear Colleagues,

Clinical Commissioning Policy 201101: Teriparatide for Osteoporosis in Men (Adults) NHS England:

NHS England published the above clinical commissioning policy as an interim statement in 2018. I am writing to update you that the policy has been refreshed and republished. The updated policy is available at:


<https://www.england.nhs.uk/publication/interim-clinical-commissioning-policy-statement-teriparatide-for-osteoporosis-in-men-adults-2/>

The reason for this refresh is as follows:

- Teriparatide is no longer listed in the 2023-25 NHS Payment Scheme (Annex A: High-Cost drugs). Therefore, acquisition costs are within the relevant tariff and not passed through to the relevant commissioner.
- The current NICE guidelines cover prescribing in women. The Internal Medicine Programme of Care has recommended that the existing NHS England interim clinical commissioning policy statement, covering the use of teriparatide for osteoporosis in men, remains available. This is intended to avoid any inequity in care based on gender. The policy statement has been amended to reflect the change in funding arrangements and that the policy is no longer interim.

There is not expected to be any change in the patient pathway or provider eligibility to deliver this service.

With best wishes,



Vinay Takwale (VT)
Medical Director NHS England South West
Region & Consultant Orthopaedic Surgeon

Tracey Williams
Principal Pharmacist